JP2016505514A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505514A5 JP2016505514A5 JP2015540267A JP2015540267A JP2016505514A5 JP 2016505514 A5 JP2016505514 A5 JP 2016505514A5 JP 2015540267 A JP2015540267 A JP 2015540267A JP 2015540267 A JP2015540267 A JP 2015540267A JP 2016505514 A5 JP2016505514 A5 JP 2016505514A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- mimetic peptide
- amino acid
- acid sequence
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- 150000001413 amino acids Chemical class 0.000 claims 24
- 239000004215 Carbon black (E152) Substances 0.000 claims 9
- 235000001014 amino acid Nutrition 0.000 claims 9
- 229930195733 hydrocarbon Natural products 0.000 claims 9
- 239000013060 biological fluid Substances 0.000 claims 6
- 150000002430 hydrocarbons Chemical class 0.000 claims 6
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 5
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- JWZFECWHKQLRGK-LLVKDONJSA-N (2r)-2-amino-2-methyldec-9-enoic acid Chemical group OC(=O)[C@@](N)(C)CCCCCCC=C JWZFECWHKQLRGK-LLVKDONJSA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 150000001294 alanine derivatives Chemical class 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010007687 Carotid artery stenosis Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000009830 antibody antigen interaction Effects 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 208000006170 carotid stenosis Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12191474 | 2012-11-06 | ||
| EP12191474.1 | 2012-11-06 | ||
| PCT/IB2013/059948 WO2014072916A1 (en) | 2012-11-06 | 2013-11-06 | Mimetic peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505514A JP2016505514A (ja) | 2016-02-25 |
| JP2016505514A5 true JP2016505514A5 (https=) | 2016-12-22 |
| JP6499967B2 JP6499967B2 (ja) | 2019-04-10 |
Family
ID=47115623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540267A Expired - Fee Related JP6499967B2 (ja) | 2012-11-06 | 2013-11-06 | 模倣ペプチド |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10087234B2 (https=) |
| EP (1) | EP2917234B1 (https=) |
| JP (1) | JP6499967B2 (https=) |
| KR (1) | KR102215175B1 (https=) |
| CN (1) | CN104768970B (https=) |
| BR (1) | BR112015010276A2 (https=) |
| CA (1) | CA2888657C (https=) |
| ES (1) | ES2859559T3 (https=) |
| MX (1) | MX364626B (https=) |
| RU (1) | RU2662973C2 (https=) |
| WO (1) | WO2014072916A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202130652A (zh) * | 2017-01-19 | 2021-08-16 | 美國衛生與公眾服務部 | Apoc-ii擬肽 |
| SG11202010017SA (en) | 2018-04-10 | 2020-11-27 | Sanofi Aventis Deutschland | Method for cleavage of solid phase-bound peptides from the solid phase |
| KR102727918B1 (ko) * | 2018-04-10 | 2024-11-11 | 사노피-아벤티스 도이칠란트 게엠베하 | 캡핑을 사용한 릭시세나티드 합성 |
| CN108948158B (zh) * | 2018-07-21 | 2021-06-15 | 河南大学 | 四连接素模拟肽tnp及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| SE0103754L (sv) | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid |
| CA2549529A1 (en) * | 2003-12-15 | 2005-06-30 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
| US7972770B2 (en) * | 2005-08-16 | 2011-07-05 | Memorial Sloan-Kettering Cancer Center | Methods of detection of cancer using peptide profiles |
| JP2010530433A (ja) * | 2007-06-20 | 2010-09-09 | メルク・シャープ・エンド・ドーム・コーポレイション | Ａｐｏａ−１ペプチド模倣体 |
| WO2012040459A2 (en) * | 2010-09-22 | 2012-03-29 | President And Fellows Of Harvard College | Beta-catenin targeting peptides and uses thereof |
| US20140213502A1 (en) * | 2011-04-29 | 2014-07-31 | United States Department of Health and Human Services | Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents |
-
2013
- 2013-11-06 ES ES13792995T patent/ES2859559T3/es active Active
- 2013-11-06 JP JP2015540267A patent/JP6499967B2/ja not_active Expired - Fee Related
- 2013-11-06 WO PCT/IB2013/059948 patent/WO2014072916A1/en not_active Ceased
- 2013-11-06 CA CA2888657A patent/CA2888657C/en active Active
- 2013-11-06 KR KR1020157013810A patent/KR102215175B1/ko not_active Expired - Fee Related
- 2013-11-06 CN CN201380057907.5A patent/CN104768970B/zh not_active Expired - Fee Related
- 2013-11-06 RU RU2015121688A patent/RU2662973C2/ru active
- 2013-11-06 US US14/440,790 patent/US10087234B2/en active Active
- 2013-11-06 BR BR112015010276A patent/BR112015010276A2/pt not_active IP Right Cessation
- 2013-11-06 MX MX2015005761A patent/MX364626B/es active IP Right Grant
- 2013-11-06 EP EP13792995.6A patent/EP2917234B1/en active Active